Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MMP12 | P39900 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295192 | 0.92 | MAPT (0.72) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL9404033 | 0.92 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL1532408 | 0.88 | MMP12 (0.79) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL5674267 | 0.87 | HDAC1 (0.75) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL11588924 | 0.86 | MAPT (0.68) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL10758583 | 0.85 | MMP12 (0.54) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL5027337 | 0.85 | HDAC1 (0.60) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL10755024 | 0.85 | TRPV1 (0.55) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL10753679 | 0.84 | FFAR1 (0.68) | TDP1FFAR1ALOX5 | |
| SCHEMBL7279036 | 0.84 | HDAC1 (0.77) | HDAC1HDAC2HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308829-B1 | A PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-06-14 | — | — | EP | claimed |
| CN-101952275-B | Modulators for amyloid protein beta | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
| US-4179564-A | 1,5,6,11-Tetrahydro[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4128717-A | Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-B]pyrazolo-[4,3-E]pyridin-11 (1H)-ones and 11 (1H)-imines | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4111940-A | ANTIINFLAMMATORY, PSYCHOTROPIC | E. R. SQUIBB & SONS, INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4062858-A | Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines | E. R. SQUIBB & SONS, INC. (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | HDAC1 1499/4885HDAC2 981/4885HDAC3 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.